Incannex Healthcare Achieves Key Milestone with Phase 2 Trial Database Lock for First-in-Class OSA Drug, Top-Line Results Expected July 2025

Reuters
18 Jun
Incannex Healthcare Achieves Key Milestone with Phase 2 Trial Database Lock for First-in-Class OSA Drug, Top-Line Results Expected July 2025

Incannex Healthcare Inc. has announced the successful completion of its RePOSA Phase 2 clinical trial database lock for IHL-42X, a drug candidate aimed at treating obstructive sleep apnoea (OSA). This milestone, achieved on June 16, 2025, enables the commencement of final statistical analysis. The top-line results of the trial are expected to be released in July 2025. The trial focuses on patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (CPAP). IHL-42X is being developed as a fixed-dose combination therapy designed to reduce apnea episodes and improve sleep quality, aiming to provide an alternative to current treatments in a field where no approved oral pharmacological treatments currently exist.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-055407), on June 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10